CPT1A and cancer: The second identified original research paper showed that iRGD-modified exosomes promote CPT1A (carnitine palmitoyltransferase 1A) downregulation in tumor tissues leading to inhibition of fatty acid oxidation; thus, since fatty acid oxidation plays a vital role in cancer chemoresistance, CPT1A siRNAs could inhibit tumor growth and reverse resistance to oxaliplatin [95].